Unlisted Deals:
ador powertron 500.00 (4,900.00 %) aitmc formerly avpl 63.00 (1.61 %) amol minechem 940.00 (3.30 %) anglo french drugs 1,020.00 (2.00 %) anugraha valve 560.00 (1.82 %) apl metals 39.00 (-2.50 %) apollo fashion 87.00 (-1.14 %) arohan 250.00 (-1.96 %) assam carbon 360.00 (2.86 %) avalokiteshvar 242.00 (0.83 %) axles india 700.00 (6.06 %) balmer lawrie 200.00 (-0.99 %) bharat hotels 380.00 (-1.30 %) bima mandi 235.00 (-2.08 %) bira 500.00 (-4.76 %) blsx 33.00 (-5.71 %) boat 1,710.00 (0.59 %) c & s electric 1,070.00 (1.90 %) cable corporation 11.10 (0.91 %) capgemini 13,600.00 (-1.45 %) care health 184.00 (2.22 %) carrier aircon 585.00 (1.74 %) cial 455.00 (-2.15 %) csk 187.00 (-2.09 %) dalmia refract 270.00 (-1.82 %) dfm foods 425.00 (-5.56 %) dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 445.00 (1.14 %) elgi ultra 400.00 elofic industries 2,850.00 (1.79 %) esl steel 42.00 (-2.33 %) fincare business 87.00 (1.16 %) fincare sfbl 205.00 (1.49 %) finopaytech limited 135.00 (-3.57 %) frick india 3,150.00 (-5.97 %) gkn driveline 1,800.00 (-0.99 %) goodluck defence 282.00 (-1.74 %) group pharma 300.00 gynofem healthcare 75.00 (2.74 %) hazira cargo terminals limited 205.00 (1.49 %) hdb financial 1,140.00 (-0.87 %) hdfc ergo 370.00 (1.70 %) hdfc securities 10,500.00 (-0.94 %) hella india 900.00 (-2.17 %) hero fincorp 1,850.00 (-3.90 %) hexaware 990.00 (-1.00 %) hicks 1,650.00 (3.13 %) hinduja leyland 262.00 (0.77 %) hira ferro 200.00 (2.56 %) honeywell electrical 7,600.00 (1.33 %) ikf finance 320.00 (3.23 %) incred holdings 155.00 (1.31 %) incred prime 10.00 (1.01 %) india carbon 1,100.00 (-1.79 %) india exposition 121.00 (0.83 %) indian potash 3,150.00 (1.61 %) indian seamless 195.00 (2.63 %) indo alusys 25.75 (-0.96 %) indofil 1,380.00 (-0.36 %) infinite computer 405.00 (1.25 %) inkel 22.00 (-2.22 %) jana small finance bank 75.00 kel 465.00 (-2.11 %) kial 132.00 (-0.75 %) klm axiva 16.00 (3.23 %) kurlon limited 1,275.00 (1.59 %) lava 40.00 (-4.76 %) lords mark 158.00 (-3.07 %) mahindra rural mrhfl 100.00 manipal housing 74.00 (2.07 %) manjushree technopack 825.00 (-2.94 %) martin & harris 820.00 (-1.20 %) matrix gas 795.00 (-0.63 %) merino 3,300.00 (1.54 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 425.00 (-2.30 %) mohan meakin 2,300.00 (-4.17 %) mohfl 19.25 (-1.28 %) msei 9.50 (-2.56 %) msil 31.00 (3.33 %) nayara energy 1,625.00 (1.56 %) nayara energy ncd 330.00 (3.13 %) ncdex 230.00 (-2.13 %) ncl buildtek 305.00 (-4.69 %) ncl holdings 106.00 (0.95 %) nsdl 1,000.00 (-0.99 %) nse india 1,800.00 (-2.70 %) onix renewable 24,500.00 (2.08 %) orbis financial 475.00 (2.15 %) oswal minerals 60.10 (-1.48 %) otis elevator 4,100.00 (2.50 %) oyo rooms 53.00 (-3.64 %) panasonic appliances 270.00 (3.05 %) paymate india 500.00 (-1.96 %) pharmeasy 9.00 (-5.26 %) pharmed limited 675.00 (2.27 %) philips domestic 575.00 (-4.17 %) philips india 925.00 (-0.54 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 260.00 (-1.89 %) rapido 16,650.00 (0.03 %) rasoi 82,000.00 (2.50 %) reliance gic 565.00 (1.80 %) ring plus aqua 600.00 (3.45 %) rrp s4e innovation 285.00 (-1.72 %) sab miller 535.00 (0.94 %) sbi amc 2,625.00 (-0.94 %) sbi general insurance 621.00 (0.16 %) scottish assam 505.00 (1.00 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,325.00 (-1.85 %) smile microfinance 51.00 (-1.92 %) sterlite grid 5 300.00 (-3.23 %) sterlite power 650.00 (-0.76 %) studds 1,400.00 (0.72 %) svsml 315.00 (2.94 %) t stanes 800.00 (1.27 %) tata capital 990.00 (-0.50 %) trl krosaki 1,750.00 (-2.78 %) urban tots 64.00 (-1.54 %) utkarsh coreinvest 270.00 (-5.26 %) vikram solar 460.00 (-3.16 %) vivriti capital 1,010.00 (-2.88 %)
×

Pharmed Ltd Annual Report & Financials

Last Traded Price 675.00 + 2.27 %

Pharmed Limited (Pharmed Limited) Return Comparision with Primex 40 Index

Periods 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years All Time
Primex-40
Pharmed Limited

PHARMED Limited Balance Sheet (In Rs. Crores)

Particulars

As at 31 March 2023

As at 31 March 2022

ASSETS                        

 

 

1) Non current assets

 

 

a)Property, Plant, and Equipment

 

 

i) Property, Plant, and Equipment

                               47.54

                               49.73

ii) Intangible Assets

                                 0.10

                                 0.12

iii) Capital work in progress

                                 0.31

                                 0.31

b) Goodwill on consolidation

                               29.11

                               29.11

c) Non current investments

                             141.06

                             113.72

c) Deferred Tax Assets (Net)

                                 2.44

                                 2.55

d) Other Non-Current Assets

                                 0.58

                                 0.49

Total non current assets

                             221.14

                             196.03

Current Assets

 

 

a) Inventories

                               31.02

                               32.24

b)  Trade Receivables

                               18.83

                               17.26

c) Cash and Cash Equivalents

                               12.73

                                 4.42

d) Short Term Loans and Advances

                                 6.06

                               12.26

Total current assets

                               68.64

                               66.18

Total Assets

                             289.78

                             262.21

EQUITY AND LIABILITIES

 

 

EQUITY

 

 

a) Equity Share capital

                                 0.86

                                 0.86

b) Other equity

                             230.19

                             198.74

Total Equity

                             231.05

                             199.60

LIABILITIES

 

 

Non-current Liabilities

 

 

a) Other Long Term liabilities

                                 4.26

                                 2.83

b) Long Trem Provisions

                                 4.99

                                 4.53

Total non current liabilities

                                 9.25

                                 7.36

Current liabilities

 

 

a)Trade payables

 

 

 Total outstanding dues of micro and small Enterprises

                               20.24

                               24.06

Total outstanding dues of creditors other than micro and small enterprises

                                 3.71

                               12.56

b) Other current liabilities

                                 4.27

                                 5.81

c) Short Term Provisions

                               21.26

                               12.82

Total current liailities

                               49.48

                               55.25

Total liabilities

                               58.73

                               62.61

Total Equity and liabilities

                             289.78

                             262.21

PHARMED  Limited Profit & Loss Statement (In Rs. Crores)

 

PARTICULARS

2023

2022

 Revenue from Operations

              425.99

              350.19

 Other Income

                  9.98

                  9.45

 Total Revenue

             435.97

             359.64

 Expenses

 

 

Purchase of Stock in Trade

              127.66

              100.37

Changes In Inventories of Stock in Trade

                  1.22

                -6.25

Employee Benefits Expense

              129.97

                97.79

Finance Cost

                  0.36

                  0.30

Other Expenses

              130.39

              110.09

Depreciation and Amortisation Expense

                  3.27

                  2.32

Total Expenses

             392.87

             304.62

Profit before Tax 

               43.10

               55.02

Tax Expense

 

 

1) Current Tax

                10.03

                13.08

2) Deferred Tax

                  0.10

                -0.39

Profit for the year

               32.97

               42.33

Earnings per Equity share (Face Value Per Share)

 

 

a) Basic (Rs.)

                76.54

                98.27

b) Diluted (Rs.)

                76.54

                98.27

PHARMED  Limited’s Cash Flow Statement (In Rs. Crores)

 

Particulars

 31st March 2023

 31 March 2022 

A. Cash Flow from Operating Activities

 

 

Profit/(Loss) Before Tax 

                43.10

                55.02

Adjustments for:

 

 

Depreciation and amortisation expenses

                  3.27

                  2.32

Finance cost

                  0.36

                  0.30

Interest Income

                -0.81

                -0.70

Net(gain) / Loss on sale of Investments

                -8.62

                -7.83

Rental Income from Investment Properties

                -0.04

                -0.04

(Gain) / Loss on sale of Asset

                  0.01

                  0.01

Cash generated from operations before working capital changes

               37.27

               49.08

Working capital changes

 

 

Adjustments for (increase)/decrease in operating Assets

 

 

Inventories

                  1.22

                -6.25

Trade receivables 

                -1.57

                -0.93

Short term loan and advances

                  5.06

                -5.23

Long term Loans and advances

                     -  

                  1.20

Other non current assets

                -0.09

                -0.16

Adjustments for (increase)/decrease in operating liabilities

 

 

Trade payables

               -12.66

                12.56

Other current liabilities

                -1.54

                  2.73

Other Long term liabilities

                  1.43

                  0.30

Long term provisions

                  0.44

                  0.64

Short Term provisions

                  8.44

                -0.07

Operating profit after working capital changes

               38.00

               53.87

Income tax paid, net of refunds

                -8.99

               -14.12

Net cash generated from operating activities

               29.01

               39.75

Cash flows from investing activities

 

 

Capital Expenditure on Fixed Assets, including capital advances

                -1.13

               -41.97

Proceeds from sale of property, plant & equipment

                  0.06

                  0.55

Purchase of long term investments

             -104.55

               -49.48

Proceeds from sale of long term investments

                85.83

                52.13

Interest Received

                  0.81

                  0.70

Rental Income Received

                  0.04

                  0.04

Net cash used in investing activities

              -18.94

              -38.03

Cash flows from financing activities

 

 

Dividend paid

                -0.36

                -0.30

Finance cost

                -1.51

                -3.01

Tax on Dividend

 

 

Net cash used in financing activities

                -1.87

                -3.31

Net increase/ (decrease) in cash and cash equivalent 

                 8.20

                -1.59

Add: Cash and Cash Equivalent at beginning of year

                  4.35

                  5.94

Cash and cash equivalents as at end of year

               12.55

                 4.35

Cash and Cash Equivalent comprise the following

 

 

Cash on hand

                  0.08

                  0.16

Balance with bank

 

 

 In Current Account

                12.65

                  4.27

Total

                12.73

                  4.43

PHARMED Limited Key Financial Ratios ( Standalone)

 

Particulars

31-Mar-23

31-Mar-22

Current Ratio (in times)

1.4

1.21

Debt-Equity Ratio (in times)

0

0

Debt Service Coverage Ratio (in times)

0

0

Return on Equity Ratio (in %)

14.44%

21.41%

Inventory Turnover Ratio (in times)

13.47

12.03

Trade Receivables Turnover Ratio (in times)

23.61

20.85

Trade Payable Turnover Ratio (in times)

4.22

3.31

Net Capital Turnover Ratio (in times)

27.45

26.89

Net Profit Ratio (in %)

7.77%

12.08%

Return on investment

6.74%

7.57%

Return on Capital Employed Ratio (in %)

19.00%

28.00%

PHARMED  Limited share Dividend History

 

Particulars 2023 2022
Dividend per Share 3.5 3.5
Retained Earnings (In Rs. Crores) 228.4 196.81

PHARMED  Limited Recent Financial Performance for FY 2023

 

Revenue from Operations: Revenue increased by ₹75.80 crores from 2022 to 2023, indicating potential growth in the core business.

Other Income: Other income remained relatively stable, with a slight increase from ₹9.45 crores in 2022 to ₹9.98 crores in 2023.

Total Revenue: Total revenue increased by ₹76.33 crores from 2022 to 2023, reflecting both core business growth and stable other income.

Total Expenses: Total expenses increased from ₹304.62 crores in 2022 to ₹392.87 crores in 2023, possibly due to increased costs.

Profit before Tax: Profit before tax decreased by ₹11.92 crores from 2022 to 2023, indicating lower pre-tax profitability in 2023.

Profit for the Year: The profit for the year decreased by ₹9.36 crores from 2022 to 2023.

Earning per Equity Share - Basic and Diluted: Basic and diluted earnings per equity share decreased significantly from ₹98.27 in 2022 to ₹76.54 in 2023, indicating reduced earnings per share.

 

 

Pharmed Limited Annual Report

Pharmed Limited Annual Report 2022-23

Download

Pharmed Limited Annual Report 2021-22

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha

News Alert